| scholarly article | Q13442814 |
| P50 | author | Ingrid Hedenfalk | Q55816354 |
| P2093 | author name string | Niklas Loman | |
| Siker Kimbung | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Genes that mediate breast cancer metastasis to the brain | Q24644008 | ||
| Latent bone metastasis in breast cancer tied to Src-dependent survival signals | Q24648828 | ||
| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 | ||
| Pericytes: developmental, physiological, and pathological perspectives, problems, and promises | Q27026645 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Mechanisms involved in breast cancer liver metastasis | Q28084024 | ||
| Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor | Q28198401 | ||
| Metadherin, a cell surface protein in breast tumors that mediates lung metastasis | Q28257184 | ||
| TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4 | Q28275478 | ||
| The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. | Q37385272 | ||
| Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer | Q37468681 | ||
| Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis | Q37501868 | ||
| Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study | Q37534923 | ||
| Long-term impact of the 70-gene signature on breast cancer outcome | Q37534934 | ||
| Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. | Q37570901 | ||
| Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents | Q37687649 | ||
| The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? | Q37694721 | ||
| Origins of metastatic traits | Q37720688 | ||
| Metastatic stem cells: sources, niches, and vital pathways | Q37720793 | ||
| 1st International consensus guidelines for advanced breast cancer (ABC 1). | Q37994463 | ||
| Dissecting the heterogeneity of triple-negative breast cancer | Q37997760 | ||
| Role of bisphosphonates in postmenopausal women with breast cancer | Q38125871 | ||
| Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow | Q38153857 | ||
| Tumor metastasis: moving new biological insights into the clinic | Q38160740 | ||
| Evaluation of osseous metastasis in bone scintigraphy | Q38283161 | ||
| Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences | Q38394007 | ||
| Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up | Q38395884 | ||
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
| Metastatic behavior of breast cancer subtypes | Q38416421 | ||
| Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 | ||
| Genes that mediate breast cancer metastasis to lung | Q29547479 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Microenvironmental regulation of metastasis | Q29547660 | ||
| The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited | Q29547915 | ||
| Dissemination and growth of cancer cells in metastatic sites | Q29555846 | ||
| Metastasis: from dissemination to organ-specific colonization | Q29614295 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| A multigenic program mediating breast cancer metastasis to bone | Q29614308 | ||
| A molecular signature of metastasis in primary solid tumors | Q29614442 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Cancer metastasis: building a framework | Q29616783 | ||
| Systemic spread is an early step in breast cancer | Q29617041 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis | Q30301242 | ||
| miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. | Q30407836 | ||
| First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. | Q30657829 | ||
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | Q30779447 | ||
| Real-time imaging reveals the single steps of brain metastasis formation | Q33519908 | ||
| Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors | Q33565565 | ||
| Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs | Q33609142 | ||
| AACR centennial series: the biology of cancer metastasis: historical perspective | Q33683443 | ||
| Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing | Q33693912 | ||
| Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers | Q33731292 | ||
| TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development | Q33834762 | ||
| RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation | Q33991449 | ||
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials | Q34054354 | ||
| From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression | Q34206149 | ||
| Selection of Successive Tumour Lines for Metastasis | Q34211379 | ||
| Interactions between cancer stem cells and their niche govern metastatic colonization | Q34239769 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Molecular basis of metastasis. | Q34304177 | ||
| Serpins promote cancer cell survival and vascular co-option in brain metastasis | Q34407528 | ||
| Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases | Q34556958 | ||
| Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells | Q34580134 | ||
| Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group | Q37119390 | ||
| The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. | Q37126990 | ||
| Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients | Q37153948 | ||
| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer | Q37198196 | ||
| Factors predicting late recurrence for estrogen receptor-positive breast cancer | Q37209554 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis | Q37302910 | ||
| Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? | Q37316222 | ||
| Prognostic factors in 1,038 women with metastatic breast cancer | Q37321930 | ||
| Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis | Q37322289 | ||
| Revision of the American Joint Committee on Cancer staging system for breast cancer | Q38432706 | ||
| New therapeutic targets for cancer bone metastasis | Q38473066 | ||
| Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. | Q38607954 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. | Q39631925 | ||
| Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. | Q40118500 | ||
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial | Q40872467 | ||
| Subtypes of breast cancer show preferential site of relapse | Q42435505 | ||
| Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry | Q42501389 | ||
| International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer | Q42595848 | ||
| Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | Q44670943 | ||
| Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases | Q45212226 | ||
| Parallel progression of primary tumours and metastases | Q45831582 | ||
| Metastatic patterns in adenocarcinoma | Q46085183 | ||
| Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. | Q46167485 | ||
| Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients | Q46580491 | ||
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. | Q46689583 | ||
| Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy | Q46693443 | ||
| Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. | Q46708743 | ||
| Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. | Q46855418 | ||
| The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer | Q46866314 | ||
| Meta-analysis of the prognostic value of circulating tumor cells in breast cancer | Q47240978 | ||
| Breast cancer subtypes predispose the site of distant metastases | Q48276930 | ||
| Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma | Q48291216 | ||
| Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q48293335 | ||
| Metastatic breast cancer subtypes and central nervous system metastases | Q48679305 | ||
| Breast cancer metastases are molecularly distinct from their primary tumors. | Q51902549 | ||
| NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. | Q53582888 | ||
| Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. | Q54542518 | ||
| Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer | Q57580663 | ||
| Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors | Q58614417 | ||
| Metastasis results from preexisting variant cells within a malignant tumor | Q67602509 | ||
| Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up | Q72576832 | ||
| Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S | Q34599128 | ||
| Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). | Q34613506 | ||
| Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. | Q34618411 | ||
| Critical determinants of metastasis | Q34654980 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Gene expression profiles of primary breast tumors maintained in distant metastases | Q34793058 | ||
| Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. | Q35012766 | ||
| Emerging strategies for treating brain metastases from breast cancer | Q35075446 | ||
| The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells | Q35079440 | ||
| Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity | Q35091690 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| The evolutionary history of lethal metastatic prostate cancer | Q35548366 | ||
| Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases | Q35549911 | ||
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group | Q35552069 | ||
| The Role of CDK4/6 Inhibition in Breast Cancer | Q35586728 | ||
| VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors | Q35621527 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. | Q35753328 | ||
| Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. | Q35800693 | ||
| International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? | Q35820247 | ||
| Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis | Q35832402 | ||
| Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination | Q35991639 | ||
| Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis | Q36210416 | ||
| Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes | Q36210944 | ||
| ID genes mediate tumor reinitiation during breast cancer lung metastasis | Q36288682 | ||
| Early-onset breast cancer--histopathological and prognostic considerations | Q36431694 | ||
| Second consensus on medical treatment of metastatic breast cancer | Q36532480 | ||
| Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications | Q36545146 | ||
| The significance of the site of recurrence to subsequent breast cancer survival. | Q36627470 | ||
| Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years | Q36672852 | ||
| Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial | Q36680024 | ||
| Genetic determinants of cancer metastasis | Q36794312 | ||
| Tumor cell dissemination: emerging biological insights from animal models and cancer patients | Q36887350 | ||
| Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. | Q36902695 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| cancer metastasis | Q120912394 | ||
| P304 | page(s) | 85-95 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Seminars in Cancer Biology | Q1908668 |
| P1476 | title | Clinical and molecular complexity of breast cancer metastases | |
| P478 | volume | 35 |
| Q37552296 | Aberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival |
| Q38791976 | Adapting coculture in vitro models of the blood-brain barrier for use in cancer research: maintaining an appropriate endothelial monolayer for the assessment of transendothelial migration. |
| Q92668355 | An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor |
| Q90608888 | An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube |
| Q64374633 | An oncolytic adenovirus targeting TGFβ inhibits pro-tumorigenic signals and produces immune activation: A novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy |
| Q37606867 | An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report |
| Q47239487 | Arachidonic Acid Metabolite as a Novel Therapeutic Target in Breast Cancer Metastasis |
| Q47601919 | Blood cadmium levels associated with short distant metastasis-free survival time in invasive breast cancer |
| Q92917139 | Breast Cancer: Proteolysis and Migration |
| Q36253544 | Breast carcinoma subtypes show different patterns of metastatic behavior |
| Q26740207 | Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy |
| Q64934986 | Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. |
| Q61813534 | Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine |
| Q99608436 | Dynamic and subtype-specific interactions between tumour burden and prognosis in breast cancer |
| Q95276510 | Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype |
| Q112610523 | Extracellular Vesicles Carry lncRNA SNHG16 to Promote Metastasis of Breast Cancer Cells via the miR-892b/PPAPDC1A Axis |
| Q38896813 | Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. |
| Q98159112 | Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer |
| Q42377416 | Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study |
| Q30361210 | Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. |
| Q33793046 | HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model |
| Q99630222 | Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database |
| Q33777055 | Is there a role for voltage-gated Na+ channels in the aggressiveness of breast cancer? |
| Q49419816 | Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality |
| Q30841338 | Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin. |
| Q91766790 | Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center |
| Q92407833 | PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer |
| Q38803038 | Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics |
| Q49544395 | Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer |
| Q64243735 | Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution? |
| Q92512356 | Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis |
| Q64076672 | Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model |
| Q92979435 | RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence |
| Q37716538 | Relationship between LINC00341 expression and cancer prognosis |
| Q93081978 | Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles |
Search more.